NASDAQ:INAB IN8bio (INAB) Stock Forecast, Price & News $2.73 -0.42 (-13.33%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$2.56▼$3.0550-Day Range$1.05▼$3.2452-Week Range$1.02▼$3.95Volume702,551 shsAverage Volume2.26 million shsMarket Capitalization$81.22 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IN8bio MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside205.3% Upside$8.33 Price TargetShort InterestHealthy1.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.10) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector685th out of 986 stocksBiological Products, Except Diagnostic Industry110th out of 165 stocks 3.3 Analyst's Opinion Consensus RatingIN8bio has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, IN8bio has a forecasted upside of 205.3% from its current price of $2.73.Amount of Analyst CoverageIN8bio has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.14% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently decreased by 88.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIN8bio does not currently pay a dividend.Dividend GrowthIN8bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INAB. Previous Next 2.6 News and Social Media Coverage News SentimentIN8bio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IN8bio this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IN8bio insiders have not sold or bought any company stock.Percentage Held by Insiders35.80% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.24% of the stock of IN8bio is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IN8bio are expected to decrease in the coming year, from ($1.10) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IN8bio is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IN8bio is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIN8bio has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IN8bio (NASDAQ:INAB) StockIN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More Receive INAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter. Email Address INAB Stock News HeadlinesJune 5, 2023 | finance.yahoo.comIN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden CrossJune 5, 2023 | finance.yahoo.comIN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual MeetingJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 5, 2023 | markets.businessinsider.comIN8bio (INAB) Gets a Buy from EF HuttonMay 24, 2023 | finance.yahoo.comIN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should KnowMay 20, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for IN8bio, Inc. Issued By HC Wainwright (NASDAQ:INAB)May 19, 2023 | americanbankingnews.comBrokers Offer Predictions for IN8bio, Inc.'s Q1 2024 Earnings (NASDAQ:INAB)May 17, 2023 | finance.yahoo.comIN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian CancerJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 12, 2023 | finance.yahoo.comIN8bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 12, 2023 | msn.comRecap: IN8bio Q1 EarningsMay 2, 2023 | benzinga.comIN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual MeetingMay 1, 2023 | finance.yahoo.comIN8bio Appoints Jeremy Graff, Ph.D., to Board of DirectorsApril 26, 2023 | finance.yahoo.comIN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual MeetingApril 26, 2023 | investorplace.comWhy Is IN8bio (INAB) Stock Up 9% Today?April 26, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on IN8bio (INAB)April 25, 2023 | seekingalpha.comIN8bio wins FDA Orphan Drug designation for glioma candidatesApril 25, 2023 | msn.comShort Volatility Alert: In8bio IncApril 25, 2023 | proactiveinvestors.comIN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatmentApril 25, 2023 | msn.comIN8bio Shares Are Pulling Back Tuesday: What's Going On?April 25, 2023 | finance.yahoo.comIN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed GlioblastomaApril 24, 2023 | msn.comWhy Are IN8bio Stock Is Soaring More Than 100% TodayApril 24, 2023 | msn.comIN8bio Soars after Promising Drug DataApril 21, 2023 | americanbankingnews.comIN8bio (NASDAQ:INAB) Stock Rating Reaffirmed by EF Hutton Acquisition Co. IApril 17, 2023 | finance.yahoo.comIN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023April 11, 2023 | finance.yahoo.comIN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual MeetingApril 1, 2023 | finanznachrichten.deIN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateSee More Headlines INAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INAB Company Calendar Last Earnings3/30/2023Today6/05/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INAB CUSIPN/A CIK1740279 Webwww.in8bio.com Phone646-600-6438FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.33 High Stock Price Forecast$14.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+205.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-125.05% Return on Assets-94.12% Debt Debt-to-Equity Ratio0.04 Current Ratio3.84 Quick Ratio3.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book2.94Miscellaneous Outstanding Shares29,750,000Free Float19,100,000Market Cap$81.22 million OptionableNot Optionable Beta0.29 Key ExecutivesMr. Tai-Wei Ho (Age 47)Co-Founder, Pres, CEO & Director Comp: $727.46kDr. Lawrence S. Lamb Ph.D. (Age 69)Exec. VP, Co-Founder & Chief Scientific Officer Comp: $482.47kMr. Patrick McCall CPA (Age 40)CFO & Sec. Comp: $519.35kDr. Kate Rochlin Ph.D. (Age 42)Chief Operating Officer Dr. Trishna Goswami M.D.Chief Medical OfficerDr. Kenneth R. LaMontagne Ph.D.Sr. VP of Bus. Devel.More ExecutivesKey CompetitorsPrecision BioSciencesNASDAQ:DTILOrchard TherapeuticsNASDAQ:ORTXCompugenNASDAQ:CGENInstil BioNASDAQ:TILJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsDimensional Fund Advisors LPBought 13,329 shares on 5/12/2023Ownership: 0.098%Sigma Planning CorpBought 104,750 shares on 5/8/2023Ownership: 0.816%Emily FairbairnBought 789,473 shares on 8/16/2022Total: $1.50 M ($1.90/share)William Tai-Wei HoBought 26,315 shares on 8/16/2022Total: $49,998.50 ($1.90/share)Lawrence LambBought 526 shares on 8/16/2022Total: $999.40 ($1.90/share)View All Insider TransactionsView All Institutional Transactions INAB Stock - Frequently Asked Questions Should I buy or sell IN8bio stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INAB shares. View INAB analyst ratings or view top-rated stocks. What is IN8bio's stock price forecast for 2023? 3 Wall Street analysts have issued 1-year price objectives for IN8bio's shares. Their INAB share price forecasts range from $3.00 to $14.00. On average, they predict the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 205.3% from the stock's current price. View analysts price targets for INAB or view top-rated stocks among Wall Street analysts. How have INAB shares performed in 2023? IN8bio's stock was trading at $2.31 at the start of the year. Since then, INAB stock has increased by 18.2% and is now trading at $2.73. View the best growth stocks for 2023 here. Are investors shorting IN8bio? IN8bio saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 137,500 shares, a drop of 88.4% from the April 30th total of 1,190,000 shares. Based on an average trading volume of 3,630,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.1% of the company's shares are sold short. View IN8bio's Short Interest. When is IN8bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our INAB earnings forecast. How were IN8bio's earnings last quarter? IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings data on Thursday, March, 30th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. When did IN8bio IPO? (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO. What is IN8bio's stock symbol? IN8bio trades on the NASDAQ under the ticker symbol "INAB." Who are IN8bio's major shareholders? IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.82%) and Dimensional Fund Advisors LP (0.10%). Insiders that own company stock include Emily Fairbairn, Kate Rochlin, Lawrence Lamb, Trishna Goswami and William Tai-Wei Ho. View institutional ownership trends. How do I buy shares of IN8bio? Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IN8bio's stock price today? One share of INAB stock can currently be purchased for approximately $2.73. How much money does IN8bio make? IN8bio (NASDAQ:INAB) has a market capitalization of $81.22 million. The company earns $-28,520,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. How can I contact IN8bio? IN8bio's mailing address is 79 Madison Avenue, New York, New York 10016. The official website for the company is www.in8bio.com. The company can be reached via phone at 646-600-6438 or via email at dbuck@soleburytrout.com. This page (NASDAQ:INAB) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.